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The dissemination of AAC(6)-I-type acetyltransferases have rendered amikacin and other aminoglycosides
all but useless in some parts of the world. Antisense technologies could be an alternative to extend the life of
these antibiotics. External guide sequences are short antisense oligoribonucleotides that induce RNase P-
mediated cleavage of a target RNA by forming a precursor tRNA-like complex. Thirteen-nucleotide external
guide sequences complementary to locations within five regions accessible for interaction with antisense
oligonucleotides in the mRNA that encodes AAC(6)-Ib were analyzed. While small variations in the location
targeted by different external guide sequences resulted in big changes in efficiency of binding to native
aac(6)-Ib mRNA, most of them induced high levels of RNase P-mediated cleavage in vitro. Recombinant
plasmids coding for selected external guide sequences were introduced into Escherichia coli harboring aac(6)-
Ib, and the transformant strains were tested to determine their resistance to amikacin. The two external guide
sequences that showed the strongest binding efficiency to the mRNA in vitro, EGSC3 and EGSA2, interfered
with expression of the resistance phenotype at different degrees. Growth curve experiments showed that E. coli
cells harboring a plasmid coding for EGSC3, the external guide sequence with the highest mRNA binding
affinity in vitro, did not grow for at least 300 min in the presence of 15 g of amikacin/ml. EGSA2, which had
a lower mRNA-binding affinity in vitro than EGSC3, inhibited the expression of amikacin resistance at a lesser
level; growth of E. coli harboring a plasmid coding for EGSA2, in the presence of 15 g of amikacin/ml was
undetectable for 200 min but reached an optical density at 600 nm of 0.5 after 5 h of incubation. Our results
indicate that the use of external guide sequences could be a viable strategy to preserve the efficacy of amikacin.
Aminoglycoside antibiotics act by interfering with the de-
coding process (12, 22, 25, 39) and are used to treat infections
caused by aerobic gram-negative or gram-positive bacteria. In
this latter case they are used in combination with other anti-
biotics (46). However, the rise in resistant and multiresistant
strains, usually harboring aminoglycoside modifying enzymes,
has limited the successful use of aminoglycosides in the treat-
ment of serious infections (17, 37). The semisynthetic amino-
glycoside amikacin (AMK) has been very useful in the treat-
ment of multiresistant infections because a limited number of
modifying enzymes, such as AAC(6)-I-type acetyltransferases,
are able to inactivate it (37). However, the spread of these
enzymes has rendered AMK all but useless in some regions of
the world (6, 30, 38, 45). Development of strategies to inhibit
the expression of resistance genes could preserve the efficacy of
AMK. Antisense oligonucleotide technologies may be an al-
ternative for this purpose. A variety of antisense strategies
have been applied before to inhibit gene expression in pro-
karyotic systems (4, 10, 23, 28, 34, 44).
RNase P, a ribozyme that includes an RNA component
(M1) that is the catalytic subunit and a cofactor protein (C5),
is responsible for generating the mature 5 end of tRNA mol-
ecules by an endonucleolytic cleavage of the precursor tRNA
(7, 15). A promising antisense strategy that takes advantage of
RNase P has been recently developed (9, 10). It is based on the
finding that RNase P can mediate cleavage of RNA molecules
other than precursor tRNA provided that an appropriate com-
plementary short oligoribonucleotide, known as the external
guide sequence (EGS), is present and forms a duplex that
results in the appropriate stem-like structure (5, 47). Oligori-
bonucleotides as short as 13 nucleotides efficiently mediate
RNA cleavage (19). Cells are transformed with a recombinant
plasmid coding for the appropriate EGS, which induces RNase
P-mediated degradation of the mRNA molecule (7, 9). This
strategy was successfully used to mediate conversion to suscep-
tibility in bacteria resistant to chloramphenicol or -lactams
(10). Furthermore, EGSs targeting essential Escherichia coli
genes were shown to reduce cell viability (23, 24). In the
present study we designed EGSs complementary to the
aac(6)-Ib mRNA and analyzed their ability to bind native
mRNA, induce RNase P-mediated degradation in vitro, and
increase susceptibility to AMK in vivo.
MATERIALS AND METHODS
Bacterial strains and plasmids. E. coli BL21(DE3) F dcm ompT hsdS(rB
mB) gal (DE3) (32) was used as host for pNW1 (28), an F derivative
including the aac(6)-Ib gene from pJHCMW1 (29) that was introduced by
conjugation. E. coli TOP10 (Invitrogen) was used for regular cloning exper-
iments. Bacterial cultures were carried out in Lennox Luria (L) broth (27).
* Corresponding author. Mailing address: Department of Biological
Science, College of Natural Science and Mathematics, California State
University Fullerton, Fullerton, CA 92834-6850. Phone: (714) 278-
5263. Fax: (714) 278-3426. E-mail: mtolmasky@fullerton.edu.
† A.J.C.S.B. and H.H. contributed equally to this study.
 Published ahead of print on 26 March 2007.
1918
 by on July 9, 2008 
a
a
c.a
sm
.o
rg
D
ow
nloaded from
 
DNA fragments, including a 27-nucleotide sequence that contains a T7 pro-
moter (GCGAAATTAATACGACTCACTATAGGG) followed by the EGS
sequence (13 nucleotides, see Fig. 1), the consensus ACCA sequence, a
hammerhead core as described by Guerrier-Takada et al. (9), and a T7
terminator sequence (TAGCATAACCCCTTGGGGCCTCTAAACGGGTC
TTGAGGGGTTTTTTG) flanked by XbaI and BamHI sites, were cloned into
pUC57 (GenBank/EMBL accession no. Y14837) to generate the recombinant
clones coding for the EGSs (named pEGS, followed by the identifier letter
and number, e.g., pEGSC3). Plasmid pRHC5 was generated by inserting a
fragment including the rnpA gene and a T7 terminator from pBSC5 (23) into
the XbaI site of the expression vector pT7-5 (33). Plasmid pJA includes the
rnpB gene under the control of a T7 promoter (41).
General DNA and RNA procedures. Plasmid DNA preparations were carried
out by using the QIAspin miniprep kit (QIAGEN). PCRs were carried out using
the HotStarTaq master mix kit (QIAGEN). All endonuclease restriction and
ligase treatments were performed according to the supplier’s recommendations
(New England Biolabs). In vitro synthesis of RNA molecules was done using a
MEGAshortscript high-yield transcription T7 kit (Ambion) according to the
protocols provided. The aac(6)-Ib mRNA was synthesized by using a linear
DNA template, including aac(6)-Ib under the control of the T7 promoter as
described before (28). M1 RNA was synthesized by using pJA as a template.
RNA labeling was carried out as described previously (28), and radioactivity was
detected with a phosphorimager (Cyclone Storage Phosphor system; Packard).
Denaturing polyacrylamide gel electrophoresis (PAGE) was performed as de-
scribed previously (28) on 6% polyacrylamide gels using a glycerol-tolerant gel
(GTG) buffer containing 16:1 (acrylamide–bis-acrylamide), 7 M urea, 89 mM
Tris, 29 mM taurine, and 0.5 mM EDTA (USB Corp.). Electrophoretic mobility
shift assays were carried out using 6% native (nondenaturing) PAGE (28).
Preparation of C5 protein. The protein C5 was overexpressed and purified
according to a procedure described previously (16, 41) with slight modifications.
E. coli BL21(DE3)(pLysE, pRHC5) was cultured in Terrific broth (35) contain-
ing 100 g of ampicillin (AMP)/ml and 34 g of chloramphenicol/ml until the
optical density at 600 nm (OD600) reached 0.6 to 0.8, when 1 mM IPTG (iso-
propyl--D-thiogalactopyranoside) was added; this was followed by incubation
overnight at 37°C. Cells were harvested by centrifugation at 7,000 rpm for 10 min;
resuspended in 0.02 volumes of buffer containing 50 mM Tris-HCl (pH 7.5), 60
mM NH4Cl, 10 mM magnesium acetate, 0.15% dithiothreitol, 42% urea, and 0.2
mM Pefabloc protease inhibitor (Roche); lysed by sonication; and treated with
6 l of 2,000 U of DNase I/ml on ice for 30 min. Cell debris was removed by
centrifugation at 8,000 rpm for 10 min. The cell extract was centrifuged at
30,000  g for 30 min, and the supernatant was collected and centrifuged for
2 h at 100,000  g. The pellet was resuspended in 10 ml of a buffer containing
50 mM Tris-HCl (pH 7.5), 1 M NH4Cl, 10 mM magnesium acetate, and 0.15%
dithiothreitol and then centrifuged at 100,000  g for 2 h. The supernatant was
subjected to dialysis overnight against a buffer containing 50 mM Tris-HCl (pH
7.5), 100 mM NH4Cl, 10 mM MgCl2, and 0.15% dithiothreitol at 20°C, followed
by centrifugation for 30 min at 15,500 rpm. The pellet was resuspended in 4 ml
of a buffer containing 0.05 M sodium acetate (pH 7.2), 0.01 M MgCl2, 7 M urea,
and 0.15% dithiothreitol. The C5 protein was then further purified by ion-
exchange column chromatography using Sephadex C50 (Amersham Biosciences)
and elution with a linear gradient 0 to 0.5 M NaCl. The C5 protein eluted at 0.3
M NaCl, and the procedure yielded a preparation that had C5 (13.5 kDa) and
one minor larger extra band.
In vitro RNase P assays. EGS-mediated cleavage of 5-end-radiolabeled
aac(6)-Ib mRNA was assayed basically as described by Li et al. (19) preincu-
bating 0.6 pmol of M1 RNA and 30 pmol of C5 protein in buffer containing 20
mM HEPES-KOH (pH 8.0), 400 mM ammonium acetate, 10 mM magnesium
acetate, and 5% glycerol at 37°C for 15 min in a final volume of 7 l. Radiola-
beled aac(6)-Ib mRNA (1.5 pmol) was preincubated with the appropriate EGS
(500 pmol) at 25°C for 2 h in a volume of 3 l. After preincubation, both
solutions were combined and incubated at 37°C for 2 h. The reaction was stopped
by the addition of 1 volume of gel loading buffer and analyzed by 6% denaturing
GTG-PAGE.
In vivo activities of EGSs. Overnight cultures of E. coli BL21(DE3)(pNW1)
harboring the recombinant plasmid coding for the EGS to be tested were diluted
to an OD600 of 0.05 in L broth containing 50 g of AMP/ml and 15 g of
AMK/ml and then incubated at 37°C for 5 h. The growth rate of the cells was
monitored by taking hourly OD600 measurements. Although the EGSs are under
FIG. 1. Nucleotide sequences of the EGSs. Nucleotide sequences of aac(6)-Ib (left) and the EGSs targeting regions A to E (right). Regions
A to E were identified previously (28).
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the control of the T7 promoter and the host E. coli BL21(DE3) includes an
IPTG-inducible T7 RNA polymerase gene, we did not observe differences in
growth in the presence or absence of the inducer. This effect has been described
before, and it was attributed to leaky transcription of the T7 RNA polymerase
gene (10).
The MICs of AMK were determined by the microdilution method (14) in the
presence of 50 g of AMP/ml to avoid loss of the plasmids coding for the EGSs.
Northern blots. Total RNA was extracted from E. coli grown on L broth
containing 50 g of AMP/ml (27). RNA samples were electrophoresed on 2.5%
formaldehyde-agarose gels and transferred to Hybond N membranes (Amer-
sham Pharmacia Biotech). Equal loading and transfer of RNA were assessed by
methylene blue staining of the membranes and ethidium bromide staining of
duplicate gels. Probes to detect aac(6)-Ib and 5S rRNA genes were radioactively
labeled with [-32P]dCTP by using a Prime-a-Gene labeling kit (Promega). The
radioactive signals were detected and quantified by using a Storm 840
PhosphorImager (Molecular Dynamics).
RESULTS
Binding to and cleavage of aac(6)-Ib mRNA in vitro. We
identified aac(6)-Ib mRNA regions accessible for interaction
with complementary oligoribonucleotides by RNase H map-
ping (28). These regions were then used as targets to design
EGSs that could induce inhibition of gene expression. We
designed eight oligoribonucleotides targeting each of the re-
gions A, B, C, and E (EGSA1 to -8, EGSB1 to -8, EGSC1 to
-8, and EGSE1 to -8), and seven targeting region D (EGSD1 to
-7) (Fig. 1). To select an EGS from each region for further
analysis, all EGSs were analyzed to determine efficiency of
binding to aac(6)-Ib mRNA and the ability to induce RNase
P-mediated degradation of aac(6)-Ib mRNA. The selection
was made based on a combination of strong binding to
aac(6)-Ib mRNA and efficient induction of RNase P-mediated
cleavage of the mRNA. Figure 2a shows electrophoretic mo-
bility shift assays obtained with EGSs targeting region C
(EGSC1 through EGSC8). EGSC3, EGSC4, and EGSC8
bound the aac(6)-Ib mRNA with the highest efficiency (Fig.
2a). However, RNase P degradation assays in vitro showed that
EGSC3 and EGSC8 induced higher levels of aac(6)-Ib mRNA
cleavage than EGSC4 (Fig. 2b). These results indicate that the
behavior of both EGSC3 and EGSC8 is approximately the
same; we decided to select EGSC3 for further analysis. An
experiment of binding in the presence of variable concentra-
tions of aac(6)-Ib mRNA further confirmed that binding of
EGSC3 is highly efficient since the lowest concentration of
mRNA assayed was sufficient to bind a high proportion of the
labeled EGS (Fig. 3a). Similar experiments led us to select
EGSA2 (region A), EGSB6 (region B), EGSD1 (region D),
and EGSE1 (region E). All five selected EGSs were tested in
binding experiments using variable concentrations of mRNA
(Fig. 3a). EGSC3 bound aac(6)-Ib mRNA with the highest
affinity; EGSA2, EGSB6, and EGSE1 showed similar binding
affinities but lower than that of EGSC3, and EGSD1 had the
lowest affinity of all selected EGSs (Fig. 3a). As expected,
neither of the two negative controls showed any aac(6)-Ib
mRNA-binding activity (Fig. 3a). One of the negative EGS
FIG. 2. Analysis of EGSs targeting region C (EGSC1 to EGSC8). (a) Binding to aac(6)-Ib mRNA. EGSs (EGSC1 through EGSC8) were end
labeled, mixed with aac(6)-Ib mRNA, and analyzed by electrophoresis in 8% native polyacrylamide gels. The EGSs used in each reaction are
indicated at the top of the gels. The control reaction was carried out in the presence of an EGS targeting the -lactamase gene. A reaction with
() or without () the addition of mRNA was performed for each EGS. (b) Induction of cleavage of aac(6)-Ib mRNA. M1 RNA was
preincubated with C5 protein at 37°C for 15 min, and radiolabeled aac(6)-Ib mRNA was preincubated with the indicated EGS (shown at the top
of the gel) at 25°C for 2 h. Both solutions were combined, incubated at 37°C for 2 h, and analyzed on 6% denaturing PAGE.
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controls was designed to target the -lactamase gene, and the
other carries a nucleotide sequence identical to that of the
mRNA (sense). The efficiencies of all five EGSs for inducing
RNase P-mediated degradation of the aac(6)-Ib mRNA were
determined by incubation in the presence of radiolabeled na-
tive mRNA and RNase P in the conditions described in the
Materials and Methods section. Figure 3b shows that all five
EGSs induced high levels of mRNA cleavage. As expected, in
the presence of the negative EGSs controls, or the absence of
RNase P or EGS, no digestion products were detected (Fig.
3b). Analysis of the results shown in Fig. 3 indicates that while
all five EGSs induced high levels of mRNA cleavage by RNase
P, they exhibited significant differences in binding affinities,
which must be sufficient to degrade most mRNA molecules
under the conditions used in these in vitro experiments.
EGS-induced susceptibility to AMK. To test the ability of
the selected EGSs to inhibit expression of AMK resistance in
E. coli harboring pNW1, a plasmid including aac(6)-Ib, we
generated recombinant plasmids with inserts that include a T7
promoter, followed by the EGS coding region; the ACCA se-
quence, which enhances RNase P-substrate recognition; and the
sequences required to generate a hammerhead ribozyme as de-
scribed before (10). E. coli BL21(DE3)(pNW1) was trans-
formed with plasmids pEGSA2, pEGSB6, pEGSC3, pEGSD1,
or pEGSE1. As controls, the same E. coli strain was transformed
with plasmids pEGSA2S, pEGSC3S, pEGSD1S, pEGSE1S, or
FIG. 3. Binding affinities of EGSs to aac(6)-Ib mRNA and induction of cleavage. (a) Binding of EGSs to aac(6)-Ib mRNA. The different
5-end-labeled EGSs and aac(6)-Ib mRNA were incubated at EGS/mRNA ratios (from left to right) of 1:0, 1:0.5, 1:1, and 1:10 as described in
Materials and Methods and then analyzed in native polyacrylamide gels. Two control reactions were carried out with an EGS designed to target
the -lactamase gene (BLA) and another with a nucleotide sequence identical to the mRNA (sense, S). (b) Induction of cleavage of aac(6)-Ib
mRNA. Cleavage reactions were carried out as described in the legend of Fig. 2. The EGSs assayed are shown at the top of the gel. Two reactions
lacking RNase P or EGS () were carried out.
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pEGSAP. Plasmids pEGSA2S, pEGSC3S, pEGSD1S, pEGSE1S
code for EGSs with sequences that are complementary to the
cognate EGSs (i.e., sense oligonucleotides), and pEGSAP
codes for an EGS that targets the alkaline phosphatase mRNA
(10). The growth rates of all of these strains were similar when
cultured in L broth containing AMP (not shown). However,
upon addition of AMK the strains harboring plasmids encod-
ing EGSA2 or EGSC3 showed growth inhibition while those
harboring plasmids coding for EGSB6, EGSD1, EGSE1, or the
control EGSs grew at approximately the same rate they did in
the absence of the aminoglycoside (Fig. 4). Since EGSC3 was
the most efficient in mediating inhibition of resistance to
AMK, the E. coli strain carrying pEGSC3 was selected for
comparison of its aac(6)-Ib mRNA levels with those in E. coli
harboring the controls pEGSC3S or pEGSAP. Total RNA was
extracted from E. coli BL21(DE3)(pNW1) also harboring
pEGSC3, pEGSC3S, or pEGSAP cultured in L broth contain-
ing AMP. Then the ratios between aac(6)-Ib mRNA and 5S
rRNA (which should be constant) were determined after quan-
tification of the signal in Northern blot hybridization experi-
ments. Figure 4 shows lower aac(6)-Ib mRNA levels in E. coli
BL21(DE3)(pNW1, pEGSC3) compared to those in the con-
trol strains. The MICs of AMK of E. coli BL21(DE3)(pNW1,
pEGSC3), E. coli BL21(DE3)(pNW1, pEGSC3S), and E. coli
BL21(DE3)(pNW1, pEGSAP) determined by using the mi-
crodilution method were 44, 96, and 96 g/ml, respectively
(average of four experiments). These results further confirmed
the inhibitory effect of EGSC3 on expression of resistance to
AMK. The high value could be due to the loss of expression of
the EGSs due to the tendency of plasmids coding for EGSs to
be lost or to suffer rearrangements. Guerrier-Takada et al.
showed that liquid cultures started to lose the plasmid after 6 h
(10). In addition, McKinney et al. (23) found that particularly
effective EGS constructs made transformants more difficult to
grow and tended to lose their plasmid vectors more rapidly and
often than did the negative control EGS constructs.
DISCUSSION
AAC(6)-Ib has been found in a large number of gram-
negative pathogenic bacteria belonging to several families and
is the most prevalent among AAC(6) type I enzymes (36, 39,
and references therein). Moreover, a recently described vari-
ant of the gene, aac(6)-Ib-cr, codes for an enzyme capable of
acetylating quinolones (26). Development of viable methods to
induce inhibition of expression of modifying enzymes, such as
antisense technologies (18), could be a strategy to preserve the
effectiveness of aminoglycosides. We have recently identified
regions accessible for binding antisense oligonucleotides in the
aac(6)-Ib mRNA (28). Thirty-nine EGSs that target 13-nucle-
otide stretches within these regions were generated and tested
to determine their mRNA binding properties, as well as their
efficiency to induce RNase P-mediated degradation in vitro.
We designed 39 different EGSs to be able to identify those
ones that show strong aac(6)-Ib mRNA binding affinity and
are highly efficient in inducing RNase P-mediated degradation
in vitro. Binding experiments showed that small changes in the
locations targeted by the EGSs can result in big differences in
binding affinity (illustrated for region C in Fig. 2). However,
under the conditions of the experiments, there was not good
correlation between binding affinity and RNase P-mediated
cleavage in vitro. An EGS targeting each one of the five re-
gions was selected using as criteria binding affinity to and
cleavage of aac(6)-Ib mRNA. Binding experiments using vari-
able quantities of mRNA showed significantly different binding
affinities, EGSC3 had the highest binding affinity of all five and
EGSD1 had the lowest (Fig. 3a). However, all of them medi-
ated high levels of mRNA cleavage (Fig. 3b). This apparent
inconsistency could occur because, unlike in the binding assays,
in the RNase P-mediated cleavage experiments the EGS/
mRNA ratio grows as mRNA molecules are degraded. The
binding affinities of all five selected EGSs must be sufficient to
degrade most mRNA molecules under the conditions used in
these in vitro experiments. EGSC3 showed a strong inhibitory
effect on expression of resistance to AMK in vivo, and EGSA2,
which was the next highest in binding efficiency, presented a
lower but significant level of inhibition of AMK resistance.
Interestingly, EGSs that induced similar levels of RNase P-
mediated cleavage but showed a lower binding affinity to the
messenger (EGSB6, EGSD1, and EGSE1) were practically
unable to reverse bacterial resistance to AMK. These findings
suggest that, at least in the case of the pJHCMW1 aac(6)-Ib
gene and in the conditions used to carry out these experiments,
in vitro binding capacity of an EGS is the best parameter to
predict its in vivo ability to inhibit gene expression. Other
groups found that variations of levels of in vivo inhibition of
gene expression were well correlated with RNase P activity in
vitro (10). We do not know the nature of this difference; it is
possible that the in vitro assays outcome is strongly dependent
on the conditions of the assays or the structure of the target
RNA. Further studies using a variety of RNA targets, loca-
tions, and conditions of in vitro binding and cleavage induction
may help clarifying this issue.
We observed that aac(6)-Ib mRNA levels in the presence of
EGSC3 were reduced by ca. 50% with respect to those in the
presence EGSC3S or AP (Fig. 4). Although the fraction of
mRNA degraded was lower than one could have expected, as
the goal is to completely silence the gene, it was comparable to
the degradation levels achieved by others (24). Further exper-
iments are presently being carried out to confirm that RNase P
is responsible for the reduction in mRNA levels and inhibition
of resistance to AMK by EGSC3.
Here we show that development of EGSs could be a way to
preserve the efficacy of aminoglycosides against the rising num-
ber of resistant pathogens. However, many problems remain to
be addressed. The large number of genetic environments in
which the aac(6)-Ib gene is found and the heterogeneity at the
N-terminal portion of the enzyme (2, 31, 37, 40, 42) probably
result in several mRNA species with different structures, not
all susceptible to a given EGS. We are analyzing the length of
mRNA species included in aac(6)-Ib genes from different
genetic environments, and we will perform computer analysis
and mapping of these mRNA species to identify a minimum
number of EGSs that can be potentially efficient at inducing
the inhibition of gene expression. As presented here, al-
though they provide proof of concept, recombinant clones
coding for EGSs do not represent a realistic recourse
against aminoglycoside-resistant pathogens. Therefore, an
active nuclease resistance form of the EGSs and a method to
ensure internalization will have to be developed. Information
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FIG. 4. Effect of EGSs on AMK-resistant E. coli. E. coli BL21(DE3)(pNW1) also harboring the recombinant plasmid coding for the indicated
EGSs (indicated to the right of each panel) were cultured as described in Materials and Methods in the presence of 50 g of AMP/ml and 15 g
of AMK/ml. Growth was monitored by measuring the OD600 at the indicated times. The controls were EGSAP, which targets the alkaline
phosphatase gene, and an EGS with the corresponding sense sequence for each EGS to be tested. RNA levels in the experiment to test activity
of EGSC3 were determined by Northern blot hybridization (inset). Total RNA was isolated from the cultures of E. coli BL21(DE3)(pNW1) also
harboring the plasmid coding for EGSC3 (C3), EGSC3S (C3S), or EGSAP (AP) and from a culture of E. coli BL21(DE3)(pNW1) (). The
samples were run in 2.5% agarose gel, transferred to nylon membranes, and hybridized using probes to detect aac(6)-Ib mRNA and 5S rRNA.
The intensity of the signals was quantified, and the ratios aac(6)-Ib/5S were calculated for each one of the samples (numbers below the Northern
blot).
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on nuclease-resistant oligoribonucleotides that induce cleav-
age of RNA by RNase P is not abundant and is mainly limited
to the eukaryotic version of the enzyme (20, 21). Since the
structural requirements of EGSs that induce cleavage by eu-
karyotic RNase P are different from those of bacterial RNase
P (8), these results might not be extrapolated to EGSs to be
used in prokaryotic systems. Some encouraging results have
recently been reported on cell internalization of oligonucleo-
tides and analogs using strategies such as liposome encapsula-
tion or attachment of cell-permeabilizing peptides to peptide
nucleic acids (3, 4, 11). In addition, since aac(6)-Ib is often
present as part of high-copy-number plasmids (45), there could
still be synthesis of enough protein molecules to confer unac-
ceptable levels of resistance in the presence of the EGS. This
problem could be solved using inhibitors of aminoglycoside-
modifying enzymes, which have been recently described (1, 13,
43). These compounds could be used in combination with
EGSs to enhance susceptibility to the antibiotic. In summary,
the results shown in the present study indicate that the devel-
opment of viable technologies involving RNase P-mediated
mRNA degradation could be an important tool to extend the
useful life of existing antibiotics to which bacteria are becom-
ing increasingly resistant.
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